Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson cardiovascular (formerly Interventional Solutions) Franchise — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
2,307
Period ended Sep 30, 2026
Change on a year earlier
+4.2%
2,213 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 2,307 | +4.2% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 2,404 | +3.9% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 2,377 | +13.0% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 2,299 | +11.5% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 2,213 | +12.6% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 2,313 | +23.5% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 2,103 | +16.4% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 2,062 | +23.5% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 1,966 | +26.2% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,873 | +15.6% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,806 | +20.2% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,669 | +52.0% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 1,558 | +47.0% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 1,620 | +54.4% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 1,503 | +37.6% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 1,098 | +7.8% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 1,060 | +10.8% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 1,049 | +0.3% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 1,092 | +15.1% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 1,019 | +14.1% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 957 | +14.5% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 1,046 | +77.3% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 949 | +30.5% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 893 | +15.4% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 836 | +12.8% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 590 | -21.3% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 727 | -0.7% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 774 | +12.8% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 741 | +13.5% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 750 | +12.4% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 732 | +14.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 686 | +10.5% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 653 | +18.1% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 667 | +16.4% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 640 | +16.6% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 621 | +28.0% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 553 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 573 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 549 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 485 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up cardiovascular (formerly interventional solutions) franchise — worldwide sales ($m)
- Cardiovascular (formerly Interventional Solutions) Franchise — U.S. sales ($M)1,397 · Q3 2026
- Cardiovascular (formerly Interventional Solutions) Franchise — International sales ($M)910 · Q3 2026
- Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide reported growth YoY (%)4.3% · Q3 2026
- Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide operational (constant-currency) growth YoY (%)4.1% · Q3 2026
- Electrophysiology sub-franchise — Worldwide sales ($M)1,487 · Q3 2026
- Abiomed (Impella heart pumps) sub-franchise — Worldwide sales ($M)412 · Q3 2026
- Shockwave (intravascular lithotripsy) sub-franchise — Worldwide sales ($M)325 · Q3 2026
- Other Cardiovascular sub-franchise — Worldwide sales ($M)81 · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide sales ($M) ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt_cardiovascular
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.